| Aurora kinase inhibitors: progress towards the clinic M Kollareddy, D Zheleva, P Dzubak, PS Brahmkshatriya, M Lepsik, ... Investigational new drugs 30, 2411-2432, 2012 | 300 | 2012 |
| Aurora kinases: structure, functions and their association with cancer. M Kollareddy, P Dzubak, D Zheleva, M Hajduch Biomedical Papers of the Medical Faculty of Palacky University in Olomouc …, 2008 | 144 | 2008 |
| Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities M Kollareddy, E Dimitrova, KC Vallabhaneni, A Chan, T Le, KM Chauhan, ... Nature communications 6 (1), 7389, 2015 | 137 | 2015 |
| Pla2g16 phospholipase mediates gain-of-function activities of mutant p53 S Xiong, H Tu, M Kollareddy, V Pant, Q Li, Y Zhang, JG Jackson, YA Suh, ... Proceedings of the National Academy of Sciences 111 (30), 11145-11150, 2014 | 91 | 2014 |
| Wnt signalling drives context-dependent differentiation or proliferation in neuroblastoma M Szemes, A Greenhough, Z Melegh, S Malik, A Yuksel, D Catchpoole, ... Neoplasia 20 (4), 335-350, 2018 | 41 | 2018 |
| The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis M Kollareddy, A Sherrard, JH Park, M Szemes, K Gallacher, Z Melegh, ... Cancer letters 403, 74-85, 2017 | 34 | 2017 |
| Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy R Hrabakova, M Kollareddy, J Tyleckova, P Halada, M Hajduch, ... Journal of proteome research 12 (1), 455-469, 2013 | 27 | 2013 |
| Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma J Bellamy, M Szemes, Z Melegh, A Dallosso, M Kollareddy, D Catchpoole, ... Frontiers in oncology 10, 818, 2020 | 20 | 2020 |
| Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation ZI Carrero, M Kollareddy, KM Chauhan, G Ramakrishnan, LA Martinez Oncotarget 7 (11), 12554, 2016 | 15 | 2016 |
| Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity L Brulíková, P Džubák, M Hajdúch, L Lachnitová, M Kollareddy, M Kolář, ... European journal of medicinal chemistry 45 (9), 3588-3594, 2010 | 15 | 2010 |
| Characterization of cancer-associated missense mutations in MDM2 KM Chauhan, G Ramakrishnan, M Kollareddy, LA Martinez Molecular & cellular oncology 3 (2), e1125986, 2016 | 8 | 2016 |
| Distinct classes of flavonoids and epigallocatechin gallate, polyphenol affects an oncogenic mutant p53 protein, cell growth and invasion in a tnbc breast cancer cell line M Kollareddy, LA Martinez Cells 10 (4), 797, 2021 | 5 | 2021 |
| ATG8-dependent LMX1B-autophagy crosstalk shapes human midbrain dopaminergic neuronal resilience N Jiménez-Moreno, M Kollareddy, P Stathakos, JJ Moss, Z Antón, ... The Journal of Cell Biology 222 (5), 2023 | 3 | 2023 |
| Aspirin reprogrammes colorectal cancer cell metabolism and sensitises to glutaminase inhibition AK Holt, AK Najumudeen, TJ Collard, H Li, LM Millett, AJ Hoskin, ... Cancer & Metabolism 11 (1), 18, 2023 | 1 | 2023 |
| PRMT5 inhibition preferentially targets MYCN-amplified neuroblastoma via altered transcriptional and splicing programmes regulating key cancer cell fitness pathways J Bojko, M Kollareddy, M Szemes, J Bellamy, E Poon, A Moukachar, ... | | 2024 |
| Novel targets for neuroblastoma therapeutics JH Park, M Szemes, M Kollareddy, K Gallacher, Z Dixon, K Malik INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 40, S38-S38, 2017 | | 2017 |
| Mutant p53 stabilizes and protects the transcription factor ETS2 from proteasomal degradation by the ubiquitin ligase COP1/DET1 ZI Carrero, M Kollareddy, KM Chauhan, G Ramakrishnan, LA Martinez Cancer Research 75 (15_Supplement), 1212-1212, 2015 | | 2015 |
| Proteomic profiling of platinum based anticancer drugs. P Dzubak, T Ozdian, D Holub, G Rylova, J Rehulka, M Kollareddy, ... Cancer Research 73 (8_Supplement), 4652-4652, 2013 | | 2013 |
| Abstract B30: Colorectal cancer HCT116 cells resistant toward a novel Aurora kinase inhibitor CYC116: Molecular hallmarks of drug resistance and pharmacologic interventions … MR Kollareddy, D Zheleva, J Srovnal, L Radova, P Dzubak, ... Clinical Cancer Research 18 (10_Supplement), B30-B30, 2012 | | 2012 |
| Colorectal cancer HCT116 cells resistant toward a novel Aurora kinase inhibitor CYC116: Molecular hallmarks of drug resistance and pharmacologic interventions restoring drug … M Kollareddy, D Zheleva, J Srovnal, L Radova, V Koudelakova, D Dolezal, ... CLINICAL CANCER RESEARCH 18 (10), 2012 | | 2012 |
